相关实验视频
Updated: Mar 6, 2026

06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.2K
甲胺保护人体胰岛素免受果糖化:一个体外生化研究
Ali Raza1, Safia Habib1, Saba Noor2
1Department of Biochemistry, Jawaharlal Nehru Medical College Faculty of Medicine, Aligarh Muslim University, Aligarh, 202002, Uttar Pradesh, India.
Current medicinal chemistry
|June 3, 2025
概括
甲胺保护人体胰岛素免受果糖化引起的损伤,防止有害的蛋白质聚合,并保持其结构. 这表明甲福明可能在控制胰岛素耐药性和相关代谢疾病方面发挥作用.
科学领域:
- 生物化学 生物化学
- 蛋白质化学 蛋白质化学
- 代谢疾病 代谢疾病
背景情况:
- 果糖可以糖化蛋白质,通过希夫基和阿马多里产品形成先进的糖化终产品 (AGEs).
- 这些过程会诱导氧化应激,改变蛋白质结构和形态,并可能导致粉样蛋白生成.
- 甲福明是治疗2型糖尿病 (T2DM) 的关键药物.
研究的目的:
- 调查甲胺对果糖化诱导的结构变化和人类胰岛素中粉样蛋白聚合的保护作用.
- 评估甲福明在抵消果糖化对胰岛素构成和功能的有害影响方面的潜力.
主要方法:
- 利用光谱技术 (UV-Vis,光,CD) 来评估胰岛素的结构.
- 量化蛋白质修饰 (碳酸含量,果糖胺) 和氨基酸残留完整性 (氨酸,氨酸).
- 使用电子显微镜和动态光散射来分析形态变化和聚合模式.
主要成果:
- 甲胺证明了果糖化胰岛素的结构和形状的度依赖的恢复.
- 提奥夫拉-T光测定和电子显微镜证实了甲胺抑制胰岛素纤维素形成的能力.
- 动态光散射表明,甲福明能保持胰岛素的水力动力半径,并作为抗氧化剂保护氨基酸残留物.
结论:
- 甲胺有效地保护胰岛素免受果糖化诱导的结构,形状和聚合相关损伤.
- 这些发现凸显了甲胺在保护胰岛素的生物活性和减轻与蛋白质聚合相关的风险方面的潜在作用.
- 需要进一步的研究来阐明甲胺对胰岛素敏感性和细胞通路的保护作用背后的分子机制.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
755
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
755
Insulin: Biosynthesis, Chemistry, and Preparation
1.7K
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
1.7K
Dipeptidyl Peptidase 4 Inhibitors
814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Oral Hypoglycemic Agents: Glinides
776
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
776
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
701
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
701
Oral Hypoglycemic Agents: Sulfonylureas
1.4K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.4K

